14-day Premium Trial Subscription Try For FreeTry Free
$0.241
+0.0155 (+6.89%)
At Close: May 07, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for ...

 12:00am, Monday, 11'th May 2020

Global Macular Edema Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025

 01:29pm, Sunday, 03'rd May 2020
May 03, 2020 (CDN Newswire via Comtex) -- A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com

 11:16am, Friday, 01'st May 2020
The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Noven Financial Group, Inc. Buys iShares 7-–… Year Treasury Bond ETF, iShares '-7 Year ...

 12:00am, Friday, 01'st May 2020

Finding The Kink In COVID-19's Armor - Preventing ARDS

 07:42am, Tuesday, 28'th Apr 2020
A treatment is needed for ARDS. Remdesivir was touted by STAT. Antiviral efficacy and side effects are under scrutiny. CytoDyn is closest to a trial readout.

Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session

 12:37pm, Thursday, 16'th Apr 2020
Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session

 12:00am, Thursday, 16'th Apr 2020

Implied Volatility Surging for Ampio (AMPE) Stock Options

 02:41pm, Thursday, 02'nd Apr 2020
Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.

Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video

 01:11pm, Thursday, 02'nd Apr 2020

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

 01:00pm, Thursday, 02'nd Apr 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat ...

 12:00am, Thursday, 02'nd Apr 2020

Ampio Suspends Patient Enrollment In Phase 3 Study Of Ampion For Severe Osteoarthritis Of The Knee And Explores Other Options To Complete Trial As A Result Of Coronavirus Concerns

 11:03am, Tuesday, 24'th Mar 2020

Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

 11:00am, Tuesday, 24'th Mar 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clin

Ampio Says Is Preparing Expanded Access FDA Protocol To 'Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with' Coronavirus

 10:33am, Tuesday, 24'th Mar 2020

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

 10:30am, Tuesday, 24'th Mar 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE